| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary biological targets of L-octanoylcarnitine are the enzymes and proteins involved in fatty acid metabolism. It interacts with medium-chain acyl-CoA dehydrogenase (MCAD), which catalyzes the initial step in the beta-oxidation of medium-chain fatty acids. As a carnitine ester, L-octanoylcarnitine is involved in the carnitine shuttle system, which transports fatty acids from the cytosol into the mitochondrial matrix for beta-oxidation. It may also interact with carnitine palmitoyltransferase 1 (CPT1) and carnitine-acylcarnitine translocase. Additionally, L-octanoylcarnitine has been studied as a potential biomarker for breast cancer, indicating its involvement in cancer metabolism.
|
|---|---|
| ln Vitro |
L-Octanoylcarnitine (0.2 mM) stimulates H2O2 release from scaffolding mitochondria (RLM) [2].
In vitro, L-octanoylcarnitine has been shown to modulate mitochondrial activity. At millimolar concentrations, it induces hydrogen peroxide (H2O2) release from rat liver mitochondria. This effect is concentration-dependent, with 0.2 mM L-octanoylcarnitine stimulating H2O2 release from scaffolding mitochondria. The compound's ability to induce mitochondrial ROS production may have implications for cellular signaling and oxidative stress. L-Octanoylcarnitine has also been studied in the context of breast cancer research, where it may serve as a potential biomarker for the disease. Its role in fatty acid metabolism makes it a useful tool for studying metabolic pathways in vitro. |
| ln Vivo |
L-octanoylcarnitine lowers nasal membrane and detrusor strength during high-fat diet (HFD) action-blood flow respiration and respiratory conductance [3].
In vivo, L-octanoylcarnitine is an endogenous metabolite present in plasma. It has been shown to lower nasal membrane and detrusor strength during high-fat diet (HFD) action-blood flow respiration and respiratory conductance. As a physiologically active form of octanoylcarnitine, it plays a role in fatty acid metabolism and energy homeostasis. It is detected in MCAD deficiency, where its levels are elevated due to impaired fatty acid oxidation. L-Octanoylcarnitine may also be involved in the metabolic alterations associated with breast cancer, making it a potential biomarker for the disease. Its in vivo effects are related to its role in fatty acid transport and mitochondrial function. |
| Enzyme Assay |
L-Octanoylcarnitine, as a small molecule metabolite, does not typically undergo classical enzyme/receptor binding assays. However, its interaction with MCAD can be studied using enzyme activity assays. A typical protocol involves incubating L-octanoylcarnitine with purified MCAD enzyme and measuring the production of octanoyl-CoA or the reduction of electron transfer flavoprotein (ETF) using spectrophotometric methods. The reaction mixture contains MCAD, L-octanoylcarnitine, CoA, and an electron acceptor such as ferricenium hexafluorophosphate. The rate of reaction is monitored by measuring the change in absorbance at a specific wavelength. The kinetic parameters (Km and Vmax) can be determined by varying the substrate concentration.
|
| Cell Assay |
For in vitro cellular experiments, cells (e.g., hepatocytes, cancer cell lines, or primary cells) are cultured in appropriate media and treated with L-octanoylcarnitine at various concentrations (typically 0.1-1 mM). After treatment, cells are harvested and analyzed for various endpoints. For studies on mitochondrial function, mitochondrial ROS production can be measured using fluorescent probes such as DCFH-DA or MitoSOX. For studies on fatty acid metabolism, the rate of fatty acid oxidation can be measured by incubating cells with radiolabeled fatty acids and monitoring the production of CO2 or acid-soluble metabolites. The duration of treatment varies depending on the experimental design but typically ranges from 1 to 24 hours.
|
| Animal Protocol |
In vivo animal experiments with L-octanoylcarnitine are not typically performed due to its role as an endogenous metabolite. However, its levels can be measured in animal models of metabolic diseases. For example, in mouse models of MCAD deficiency or high-fat diet-induced obesity, plasma L-octanoylcarnitine levels can be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The compound can also be administered exogenously to study its effects on metabolism. Dosing regimens and routes of administration vary depending on the experimental objectives. Blood and tissue samples are collected for metabolomic analysis.
|
| ADME/Pharmacokinetics |
L-Octanoylcarnitine is an endogenous metabolite with a molecular weight of 287.4 g/mol and a molecular formula of C15H29NO4. It is soluble in DMSO and should be stored at -20degC. As an endogenous compound, its pharmacokinetic properties are governed by normal metabolic processes. It is synthesized in the body from carnitine and octanoic acid and is involved in fatty acid transport and oxidation. L-Octanoylcarnitine is present in plasma and other biological fluids. Its levels can be altered in metabolic disorders such as MCAD deficiency. Exogenous administration of L-octanoylcarnitine would be subject to normal metabolic turnover and clearance.
|
| Toxicity/Toxicokinetics |
L-Octanoylcarnitine is an endogenous metabolite and is generally considered safe at physiological concentrations. However, elevated levels of L-octanoylcarnitine are associated with metabolic disorders such as MCAD deficiency, indicating that abnormal accumulation can be pathological. In vitro studies have shown that L-octanoylcarnitine at millimolar concentrations can induce mitochondrial ROS production, which may contribute to oxidative stress. At lower, physiologically relevant concentrations, the compound is not considered toxic. As a research compound, L-octanoylcarnitine should be handled with standard laboratory precautions. It is for research use only and not for human therapeutic use.
|
| References |
|
| Additional Infomation |
O-O-capryl-L-carnitine is the L-enantiomer of O-capryl carnitine and plays a role in human metabolism. It is an O-capryl carnitine, as well as a saturated fatty acyl-L-carnitine and a medium-chain fatty acyl-L-carnitine. It is the enantiomer of O-capryl-D-carnitine. L-capryl carnitine has been reported to be detected in both Homo sapiens and Euglena, with relevant data available. See also: Capryl carnitine (note moved to).
L-Octanoylcarnitine is the physiologically active form of octanoylcarnitine and is a plasma metabolite. It is a medium-chain acylcarnitine formed by the esterification of carnitine with octanoic acid. L-Octanoylcarnitine plays a crucial role in the transport of fatty acids into mitochondria for beta-oxidation. It is detected in MCAD deficiency, a metabolic disorder characterized by impaired oxidation of medium-chain fatty acids. L-Octanoylcarnitine has also been identified as a potential biomarker for breast cancer. Its levels in plasma may reflect alterations in fatty acid metabolism associated with cancer. The compound is available as a research chemical and is used in studies of metabolism, mitochondrial function, and cancer biology. |
| Molecular Formula |
C15H29NO4
|
|---|---|
| Molecular Weight |
287.39506
|
| Exact Mass |
287.21
|
| CAS # |
25243-95-2
|
| Related CAS # |
Octanoylcarnitine chloride;14919-35-8;L-Octanoylcarnitine hydrochloride;54377-02-5;L-Octanoylcarnitine-d3;204259-56-3
|
| PubChem CID |
11953814
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.104
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
20
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C
|
| InChi Key |
CXTATJFJDMJMIY-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C15H29NO4/c1-5-6-7-8-9-10-15(19)20-13(11-14(17)18)12-16(2,3)4/h13H,5-12H2,1-4H3/t13-/m1/s1
|
| Chemical Name |
(3R)-3-octanoyloxy-4-(trimethylazaniumyl)butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~347.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4795 mL | 17.3974 mL | 34.7947 mL | |
| 5 mM | 0.6959 mL | 3.4795 mL | 6.9589 mL | |
| 10 mM | 0.3479 mL | 1.7397 mL | 3.4795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
